SPOTLIGHT: Exelixis gains $35M milestone payment from GSK


GSK has exercised its option to exclusively license Exelixis' XL880 for further development. Exelixis gains a milestone payment of $35 million, as well as additional payments upon the attainment of specific development and commercialization milestones. Release

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.